title: Intravitreal triamcinolone acetonide as an adjuvant in the management of acute retinal necrosis.
abstract: OBJECTIVE
  To determine the role of intravitreal triamcinolone acetonide (IVTA) as an adjuvant in the management of acute retinal necrosis (ARN).
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  Four eyes of 4 patients diagnosed with ARN were studied.
  
  
  METHODS
  This pilot case series included 4 patients who presented with clinical features suggestive of ARN. IVTA was injected 1 to 2 weeks after initiation of antiviral therapy and concurrent usage of oral corticosteroids. The disease course and clinical outcome were observed. The patients received additional treatment depending on the sequelae of ARN.
  
  
  RESULTS
  Signs of reduction in vitritis and resolution of retinitis were observed as early as 1 week after IVTA was administered. In all 4 patients, inflammation promptly resolved with no untoward effects like raised intraocular pressure or worsening of the retinitis. A final visual acuity of 20/40 or better was achieved in 3 of 4 patients after appropriate treatment of ARN-related complications.
  
  
  CONCLUSIONS
  Intravitreal triamcinolone under antiviral cover could be a useful adjunct to systemic steroids in the treatment of ARN.
authors.affiliation: L V Prasad Eye Institutes, GMRV Campus, Visakhapatnam, India.
authors.forename: Himadri
authors.initials: H
authors.lastname: Choudhury
authors.affiliation: L V Prasad Eye Institutes, GMRV Campus, Visakhapatnam, India.
authors.forename: Animesh
authors.initials: A
authors.lastname: Jindal
authors.affiliation: L V Prasad Eye Institutes, GMRV Campus, Visakhapatnam, India.
authors.forename: Kopal
authors.initials: K
authors.lastname: Mithal
authors.affiliation: L V Prasad Eye Institutes, GMRV Campus, Visakhapatnam, India.
authors.forename: Abhishek C
authors.initials: AC
authors.lastname: Bawdekar
authors.affiliation: L V Prasad Eye Institutes, GMRV Campus, Visakhapatnam, India. Electronic address: avinash@lvpei.org.
authors.forename: Avinash
authors.initials: A
authors.lastname: Pathengay
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000998:Antiviral Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005128:Eye Diseases / Q000503:physiopathology; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D015882:Retinal Necrosis Syndrome, Acute / Q000188:drug therapy* / Q000503:physiopathology; D012173:Retinitis / Q000503:physiopathology; D014222:Triamcinolone Acetonide / Q000009:adverse effects / Q000627:therapeutic use*; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body / Q000503:physiopathology; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir